ALTEOGEN stock

196170 · KRX · KRW

Compare ALTEOGEN
₩168,700.00Change from previous close: −2.49%Absolute change: −₩4,300.00

Close · November 18, 2026

Price history

−60.77% over the period

1 year: from ₩430,000.00 (November 18, 2025) to ₩168,700.00 (November 18, 2026), −60.77%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 18, 2026₩168,700.00
October 30, 2026₩211,500.00
September 30, 2026₩254,500.00
August 31, 2026₩307,500.00
July 31, 2026₩237,307.69
June 30, 2026₩277,692.31
May 29, 2026₩283,846.16
April 30, 2026₩283,461.53
March 31, 2026₩262,692.31
February 27, 2026₩313,461.53
January 30, 2026₩317,692.31
December 30, 2025₩345,769.22
November 28, 2025₩410,000.00
November 18, 2025₩430,000.00

At a glance

  • The company

    Develops long-acting biobetters, antibody-drug conjugates, and antibody biosimilars for cancer, hemophilia and other diseases

  • Latest results

    Quarter to September 30, 2026 · EPS ₩691.68 (estimate ₩607.73)

TickerLandia's take on ALTEOGEN

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low₩152,500.00
52-wk high₩437,692.30

−61.46% from the 52-week high

Analysts · 6 analysts

Average target₩358,333.34+112.41% vs. price

Buy 5 · Hold 1 · Sell 0 · Buy

TickerLandia Fingerprint: ALTEOGEN

Compared with similar companies: very weak momentum, very high profitability, and very high risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

ALTEOGEN is pricier than similar companies

ALTEOGEN's P/E (trailing 12 months): 97.1, +109% against the median of a group of 8 similar companies (46.5).

Compared with 8 similar companies

ALTEOGEN's metrics compared with similar companies
MetricALTEOGENPosition in the groupBand
P/E (trailing 12 months)97.1High
Forward P/E32.0Middle
Operating margin47.2%High
ROE35.6%High
Debt/equity0.01Low

Grey band: the middle half of the group; tick: the median; dot: ALTEOGEN. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

₩68.89B

Latest quarter · Q2 2026

Net income

₩28.42B

Latest quarter · Q2 2026

Quarterly net margin

41.2%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
₩12.25T
P/E
97.1
EPS
₩2,610.42
Volume
452.34K
Daily trading
€55.83M
Dividend yield
0.17%
Last ex-dividend on December 29, 2025

How ALTEOGEN is changing

All results
  • Revenue grew 38.5% a year on average over the last 5 years

  • Operating margin rose from −102.0% to 49.5%

  • Free cash flow equal to 71% of net income

Returns

ALTEOGEN returns with dividends

₩1,000 invested in ALTEOGEN 5 years ago, on November 18, 2021, would be worth ₩3,814 today: +281.41% in total, +30.71% per year. This is the price return only: dividends are excluded.

PeriodALTEOGEN₩1,000 becomes
1 month−29.41%₩706
6 months−38.65%₩613
Year to date−51.21%₩488
1 year−60.74%₩393
3 years+222.99%₩3,230
5 years+281.41%₩3,814
10 years+4,977.27%₩50,773

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

ALTEOGEN: technical analysis

ALTEOGEN is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 60.8% below its all-time closing high (₩430,000.00, November 18, 2025).

Trend
Downward
RSI (14 sessions)
30
Below 30: a strong fall in a short time
vs 200-session average
−36.91%

Active signals

  • RSI below 30: the stock has fallen a lot in a short time.

Support and resistance

Price areas where ALTEOGEN has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance₩253,205.13+50.09%3 touches, last on June 24, 2026
  2. Resistance₩244,935.90+45.19%3 touches, last on October 21, 2026
  3. Resistance₩207,000.00+22.70%2 touches, last on October 15, 2026
  4. Last price₩168,700.00
  5. No support below: the price is near the lows of the year

Volatility and risk

Volatility (60 sessions, annualised)
58.2%
Largest fall in the last year
−60.84%

In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

ALTEOGEN: seasonality

Average monthly price change over 12 years

−3.7%Jan+13.3%Feb+7.5%Mar+4.7%Apr+11.3%May+9.5%Jun+3.2%Jul+1.7%Aug+1.0%Sep−3.6%Oct+7.9%Nov+9.4%Dec

Over the last 12 years, the strongest month for ALTEOGEN has been February: +13.28% on average, positive in 8 years out of 12. The weakest has been January: −3.67% on average, positive in 5 years out of 12. November, the current month, has been positive in 8 years out of 11 (+7.92% on average).

Show chart data
MonthAverageMedianPositive years
January−3.67%−4.34%5 of 12
February+13.28%+3.38%8 of 12
March+7.55%+4.35%8 of 12
April+4.73%+1.56%7 of 12
May+11.26%−1.70%5 of 12
June+9.55%+8.08%8 of 12
July+3.16%−0.29%6 of 12
August+1.70%+2.96%8 of 12
September+1.00%−0.92%6 of 12
October−3.56%−5.98%4 of 12
November+7.92%+7.99%8 of 11
December+9.37%+10.19%9 of 11

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

ALTEOGEN and its competitors

ALT-P1, a long-acting human growth hormone in a Phase IIa trial, and ALT-Q2, a coagulation factor VII product for hemophilia, anchor the development pipeline of ALTEOGEN Inc. Its oncology candidates include ALT-P7, a targeted drug for breast and gastric cancer in Phase I, and ALT-Q5, an antibody-drug conjugate for ovarian cancer built on its NexMab ADC technology.

Headquarters
Daejeon, South Korea
Employees
181
Founded
2008
Chief executive
Soon-Jae Park
ALTEOGEN and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ALTEOGEN196170$9.17B47.2%97.1−38.65%
Genscript Biotech1548$8.83B14.9%—+111.76%
Haisco Pharmaceutical Group002653$9.79B21.1%50.6+4.89%
Akeso9926$7.6B-30.7%—−48.20%
Pharmaron Beijing300759$11.45B14.0%42.4+49.16%
Sino Biopharmaceutical1177$12.49B28.2%36.7+0.57%

Same industry or related industries, similar size. Compare ALTEOGEN with its competitors · Full profile